,,ii  #aag? ,,congress  #b;d ,session   
,s4 #dcij  ,,9 ,,! ,,s5ate ,,( ,,!      
,,unit$ ,,/ates  ,june #ad1 #bjbb,mr4   
,hick5loop] introduc$ ! foll[+ bill2 :i*
 0 read twice & ref]r$ to ! ,committee  
on ,heal?1 ,education1 ,labor1 &        
,p5sions  ,a ,,bill  ,to require summ>y 
approval in=mation ) respect to c]ta9   
approv$ drugs & biological products4    
#a4 ,%ort title ,?is ,act may be cit$ z 
! ,accel]at$ ,approval ,transp>5cy ,act4
  #b4 ,summ>y approval in=mation ,)     
respect to ea* new drug application = a 
new molecul> entity approv$ "u section  
#eje7;c7 ( ! ,f$]al ,food1 ,drug1 &     
,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;c77 
or biological product lic5s$ "u section 
#cea7;a7 ( ! ,public ,heal? ,s]vice ,act
 7#db ,u4,s4,c4 #bfb7;a77 pursuant to   
accel]at$ approval "u section #ejf7;c7 (
 ! ,f$]al ,food1 ,drug1 & ,cosmetic ,act
 7#ba ,u4,s4,c4 #cef7;c771 ! ,secret>y (
 ,heal? & ,human ,s]vices %all provide =
 ! drug or biologic action package a    
summ>y ( ! basis = approval1 includ+1 z 

relates to su* new molecul> entity1 :e!r
 an advisory committee meet+ 0 held & a 
rationale = a det]m9ation by ! ,secret>y
 t a surrogate endpo9t is reasonably    
likely to pr$ict cl9ical b5efit4